#SOHO2024: Mantle cell lymphoma

To update you on the exciting content presented at the Society of Hematologic Oncology (SOHO) 2024 Annual Meeting, we have collated our social media coverage. Catch up on our live social media coverage relating to mantle cell lymphoma below.

CONGRESS | #SOHO2024
Reid Merryman, @DanaFarber, discusses evolving role of MRD in #lymphoma and the advancements in cfDNA assays for improving sensitivity of ctDNA detection, including ClonoSeq(R), CAPP-Seq, Avenio, PhaseED-Seq, and MAESTRO. Several clinical trials are adapting… pic.twitter.com/Tml1PRIGvE

— Lymphoma Hub (@lymphomahub) September 10, 2024

CONGRESS | #SOHO2024@sairah__ahmed, @MDAndersonNews, discussed real world data on CAR T-cell therapy for MCL. Real-world effectiveness & safety of brexu-cel in patients with R/R MCL were similar to ZUMA-2 trial results:
▪️ CIBMTR subgroup analysis by prior treatment: ORR was… pic.twitter.com/R0RWi4l1xy

— Lymphoma Hub (@lymphomahub) September 10, 2024

CONGRESS | #SOHO2024 | POSTER@michaelwangmd @MDAndersonNews presents data from the phase III SYMPATICO trial, showing improved safety and efficacy of ibrutinib + venetoclax in patients with R/R MCL and TP53 mutations. N=74, mPFS=20.9, mOS=47.1 mo. #lymphoma #lymsm… pic.twitter.com/Q0kHIXayTJ

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024@KrishPatelMD, @ProvSwedish, discusses novel investigational agents for the treatment of MCL, such as molecular glues/degraders, ADCs, novel CAR T cells, and BsAbs. Notable “off the shelf” therapies with meaningful activity include glofitimab monotherapy and… pic.twitter.com/vsVb5bgPuY

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Craig Portell, @UVACancerCenter, discusses sequencing therapies in R/R MCL. He advises considering prior exposure to BTKi when managing relapse in MCL. If the patient hasn't been previously exposed, a BTKi should be started. If they’re actively on a BTKi at… pic.twitter.com/TccEL2LdWM

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | #SOHO2024
Nina Wagner Johnston, @HopkinsMedicine, discusses the role of BTKi in frontline treatment of MCL. In older patients, addition of continuous ibrutinib to bendamustine and rituximab (BR) improved PFS however, worsened OS due to toxicity, while continuous… pic.twitter.com/KGvo5zQ1hB

— Lymphoma Hub (@lymphomahub) September 9, 2024

CONGRESS | POSTER | #SOHO2024 | Tycel Phillips, MD @LymphClinician from @cityofhope introduced the phase III GLOBRYTE study which will compare fixed duration glofitamab monotherapy with rituximab+BR/Len for R/R #mantlecelllymphoma (N=182), with a primary endpoint of PFS.… pic.twitter.com/J4lBr0bk5Y

— Lymphoma Hub (@lymphomahub) September 4, 2024